CIK 0001664710 · Non-accelerated filer<br>Smaller reporting company
Keros Therapeutics, Inc.
Sign in to watch- Ticker
- KROS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 811173868
- Phone
- 617-314-6297
- Business address
- 1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421
- Open-market buys, last 90 days
- $10,270
- in 1 filing
- Open-market sales, last 90 days
- $101,136
- in 4 filings, $6K under 10b5-1 plans
Net −$90,866. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 78 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-11-29 | Pontifax Management 4 G.P. (2015) Ltd. 10% owner | Option exercise | −1,723 | $0.00 | $0 | 1,121,045 |
| 2022-11-29 | Pontifax Management 4 G.P. (2015) Ltd. 10% owner | Option exercise | −1,914 | $0.00 | $0 | 1,226,412 |
| 2022-11-29 | Pontifax Management 4 G.P. (2015) Ltd. 10% owner | Option exercise · Call Options (obligation to sell) | −3,539 | 0 | ||
| 2022-11-29 | Pontifax Management 4 G.P. (2015) Ltd. 10% owner | Option exercise · Call Options (obligation to sell) | −1,723 | 0 | ||
| 2022-11-29 | Pontifax Management 4 G.P. (2015) Ltd. 10% owner | Option exercise · Call Options (obligation to sell) | −1,914 | 0 | ||
| 2022-11-29 | Nussbaum Ran Director | Option exercise | −3,539 | $0.00 | $0 | 2,284,612 |
| 2022-11-29 | Nussbaum Ran Director | Option exercise | −1,723 | $0.00 | $0 | 1,121,045 |
| 2022-11-29 | Nussbaum Ran Director | Option exercise | −1,914 | $0.00 | $0 | 1,226,412 |
| 2022-11-29 | Nussbaum Ran Director | Option exercise · Call Options (obligation to sell) | −3,539 | 0 | ||
| 2022-11-29 | Nussbaum Ran Director | Option exercise · Call Options (obligation to sell) | −1,723 | 0 | ||
| 2022-11-29 | Nussbaum Ran Director | Option exercise · Call Options (obligation to sell) | −1,914 | 0 | ||
| 2022-11-29 | Kariv Tomer Director | Option exercise | −3,539 | $0.00 | $0 | 2,284,612 |
| 2022-11-29 | Kariv Tomer Director | Option exercise | −1,723 | $0.00 | $0 | 1,121,045 |
| 2022-11-29 | Kariv Tomer Director | Option exercise | −1,914 | $0.00 | $0 | 1,226,412 |
| 2022-11-29 | Kariv Tomer Director | Option exercise · Call Options (obligation to sell) | −3,539 | 0 | ||
| 2022-11-29 | Kariv Tomer Director | Option exercise · Call Options (obligation to sell) | −1,723 | 0 | ||
| 2022-11-29 | Kariv Tomer Director | Option exercise · Call Options (obligation to sell) | −1,914 | 0 | ||
| 2022-07-15 | Lachey Jennifer Chief Scientific Officer | Option exercise | +46,034 | $0.30 | $14K | 141,134 |
| 2022-07-15 | Lachey Jennifer Chief Scientific Officer | Sale | −46,034 | $30.00 | $1.4M | 95,100 |
| 2022-07-15 | Lachey Jennifer Chief Scientific Officer | Option exercise · Employee Stock Option (right to buy) | −46,034 | 8,755 |
Page 8 of 9 · 173 trades